

## 200 Articles Every Student of Nephrology Should Know

---

**These are articles which every student of Nephrology should know. Majority of them are free on web. Paste the title of article on Google search bar to reach it. Others can be obtained from any reputed library like Sri Venkateswara Institute of Medical Sciences, Tirupati. Senior Nephrologists are most welcome to suggest the articles to be included in this list.**

1. Primary nephrotic syndrome in children: Clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A report of the International Study of Kidney Disease in Children. *Kidney International*, Vol. 20 (1981), pp. 765—771 (Free)
2. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. *Lancet*. 1974 Aug 24;2(7878):423-7.
3. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA. *Clin Nephrol*. 1995 Feb;43(2):84-8.
4. Kriz W. The pathogenesis of 'classic' focal segmental glomerulosclerosis—lessons from rat models. *Nephrol Dial Transplant*. 2003 Aug;18Suppl 6:vi39-44.(Free)
5. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. *Lancet*. 1974 Sep 7;2(7880):556-60.
6. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. *Q J Med*. 1987 Sep;64(245):709-27.
7. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. *J Am Soc Nephrol*. 1999 Aug;10(8):1772-7.(Free)
8. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: a randomised controlled trial. *Lancet*. 1999 Mar 13;353(9156):883-7.
9. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. *J Am Soc Nephrol*. 2002 Jan;13(1):142-8 .(Free)
10. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthouix F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G,

Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: pathology, definitions, correlations, and reproducibility. *Kidney Int.* 2009 Sep;76(5):546-56. doi: 10.1038/ki.2009.168. Epub 2009 Jul 1. (Free)

12. Ponticelli C, Zucchelli P, Imbasciati E. et al. Controlled trial of methyl prednisolone and chlorambucil idiopathic membranous nephropathy. *N Engl J Med* 320: 8-13, 1984. (Free)
13. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, et al.: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. *Kidney Int* 48: 1600-1604, 1995. (Free)
14. Ponticelli C, Zucchelli P, Passerini. et al. Methyl prednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. *N Engl J Med* 327: 599-603, 1992. (Free)
15. Vivekanand Jha, Anirban Ganguli, Tarun K. Saha, Harbir S. Kohli, Kamal Sud, Krishan L. Gupta, Kusum Joshi, and Vinay Sakhuja: A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy *J Am Soc Nephrol* 18: 1899-1904, 2007. (Free)
16. Beck LH Jr, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med* 2009;361:11-21. (Free)
17. Debiec H, Guignon V, Mougnot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. *N Engl J Med* 2002;346:2053-60. (Free)
18. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis The classification of glomerulonephritis in systemic lupus erythematosus revisited *Kidney International*, Vol. 65 (2004), pp. 521-530 (Free)
19. Austin HA 3rd, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. *N Engl J Med.* 1986 Mar 6;314(10):614-9.

20. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. *Ann Intern Med.* 1996 Oct 1;125(7):549-57.
21. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. *Ann Intern Med.* 2001 Aug 21;135(4):248-57.
22. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol.* 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15. (Free)
23. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Immunosuppressive Therapy in Lupus Nephritis: The Euro-Lupus Nephritis Trial, a Randomized Trial of Low-Dose Versus High-Dose Intravenous Cyclophosphamide. *Arthritis Rheum.* 2002 Aug;46(8):2121-31. (Free)
24. Sequential therapies for proliferative lupus nephritis. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. *N Engl J Med.* 2004 Mar 4;350(10):971-80. (Free)
25. Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P, Ponticelli C. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. *Nephrol Dial Transplant.* 2006 Jun;21(6):1541-8. Epub 2006 Feb 2. (Free)
26. Mogensen CE, Christensen CK, Vitting E. The Stages in Diabetic Renal Disease With Emphasis on the Stage of Incipient Diabetic Nephropathy. *Diabetes* ,32,S2,JUNE 1983, 64 (Free)
27. Ravid M, Brosh D, Levi Z, Bar-Dayana Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med.* 1998 Jun 15;128(12 Pt 1):982-8.
28. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001;345:851-860. (Free)
29. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang G, Shahinfar S; RENAAL Study Investigators. Effects of

- losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*. 2001 Sep 20;345(12):861-9. (Free)
30. Hans-Henrik Parving, Hendrik Lehnert, Jens Bröchner-Mortensen, Ramon Gomis, Steen Andersen, Peter Arner. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. *N Engl J Med* 2001; 345:870-878 (Free)
31. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med*. 2006 Jan 12;354(2):131-40. (Free)
32. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31 (Free)
33. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA; Renal Pathology Society. Pathologic classification of diabetic nephropathy. *J Am Soc Nephrol*. 2010 Apr;21(4):556-63. doi: 10.1681/ASN (Free)
34. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16:31-41
35. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (March 1999). "A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group". *Annals of Internal Medicine* 130 (6): 461–70. doi:10.7326/0003-4819-130-6-199903160-00002. PMID 10075613.
36. Andrew S. Levey, MD; Lesley A. Stevens, MD, MS; Christopher H. Schmid, PhD; Yaping (Lucy) Zhang, MS; Alejandro F. Castro III, MPH; Harold I. Feldman, MD, MSCE; John W. Kusek, PhD; Paul Eggers, PhD; Frederick Van Lente, PhD; Tom Greene, PhD; Josef Coresh, MD, PhD, MHS, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A New Equation to Estimate Glomerular Filtration Rate *Ann Intern Med*. 2009;150(9):604-612. (Free)
37. V Arroyo, P Ginès, A L Gerbes, F J Dudley, P Gentilini, G Laffi, T B Reynolds, H Ring-Larsen J Schölmerich. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology*. Volume 23, Issue 1, pages 164–176, January 1996 (Free)
62. Francesco Salerno, Alexander Gerbes, Pere Ginès, Florence Wong, and Vicente Arroyo Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis *Gut*. Sep 2007; 56(9): 1310–1318. (Free)
63. Joel L. Moake, Thrombotic Microangiopathies. *N Engl J Med* 2002; 347:589-600 August 22, 2002.

64. Billy G. Hudson, Karl Tryggvason, Munirathinam Sundaramoorthy, Eric G. Neilson  
Alport's Syndrome, Goodpasture's Syndrome, and Type IV Collagen N Engl J Med  
2003; 348:2543-2556.
65. Harrison EG Jr, McCormack LJ. Pathologic classification of renal arterial disease in  
renovascular hypertension. Mayo Clin Proc. Mar 1971;46(3):161-7
66. Krijnen P, van Jaarsveld BC, Steyerberg EW, Man in 't Veld AJ, Schalekamp MA,  
Habbema JD. A clinical prediction rule for renal artery stenosis. Ann Intern Med. 1998  
Nov 1;129(9):705-11.
67. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A,  
Woittiez AJ, Bartelink AK, Man in 't Veld AJ, Schalekamp MA. The effect of balloon  
angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal  
Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000 Apr  
6;342(14):1007-14. (Free)
68. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B,  
Huysmans FT, SchultzeKool LJ, Rutten MJ, Doorenbos CJ, Aarts JC, Rabelink TJ,  
Plouin PF, Raynaud A, van Montfrans GA, Reekers JA, van den Meiracker AH,  
Pattynama PM, van de Ven PJ, Vroegindewey D, Kroon AA, de Haan MW, Postma  
CT, Beutler JJ. Stent placement in patients with atherosclerotic renal artery stenosis  
and impaired renal function: a randomized trial. Ann Intern Med. 2009 Jun  
16;150(12):840-8, W150-1. Epub 2009 May 4.
69. The ASTRAL Trial Investigators: Revascularization versus medical therapy for renal-  
artery stenosis. N Engl J Med 361:1953-1962, 2009.
70. Cooper CJ, Murphy TP, Matsumoto A, et al: Stent revascularization for the  
prevention of cardiovascular and renal events among patients with renal artery  
stenosis and systolic hypertension: rationale and design of the CORAL trial. Am  
Heart J 152:59-66, 2006.
71. Horacio J. Adrogué, , Nicolaos E. Madias, Hyponatremia. N Engl J Med 2000;  
342:1581-1589.
72. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W.  
Prevention of radiographic-contrast-agent-induced reductions in renal function by  
acetylcysteine. N Engl J Med. 2000 Jul 20;343(3):180-4. (Free)
73. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008 Apr  
15;51(15):1419-28. doi: 10.1016/j.jacc.2007.12.035. (Free)
74. Battle DC, Hizon M, Cohen E, Gutterman C, Gupta R. The use of the urinary anion  
gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988 Mar  
10;318(10):594-9.

75. Xavier Bosch, Esteban Poch, Josep M. Grau. Rhabdomyolysis and Acute Kidney Injury. *N Engl J Med* 2009; 361:62-72.
76. Chugh KS. Snake-bite-induced acute renal failure in India. *Kidney Int.* 1989 Mar;35(3):891-907.
77. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Quality Initiative workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204-R212. (Free)
78. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11: R31 (Free)
79. Robert W Schrier Acute renal failure *Kidney Int* 15: 205-216 (Free)
80. Espinel CH. The FENa test. Use in the differential diagnosis of acute renal failure. *JAMA.* 1976 Aug 9;236(6):579-81.
81. Thompson BC, Kingdon E, Johnston M, Tibballs J, Watkinson A, Jarmulowicz M, Burns A, Sweny P, Wheeler DC Transjugular kidney biopsy. *Am J Kidney Dis.* 2004 Apr;43(4):651-62.
82. Humes HD, MacKay SM, Funke AJ, Buffington DA Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. *Kidney Int.* 1999 Jun;55(6):2502-14.(Free)
83. Schiff H, Lang SM, Fischer R Daily hemodialysis and the outcome of acute renal failure. *N Engl J Med.* 2002 Jan 31;346(5):305-10.(Free)
84. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. *Lancet.* 2000 Jul 1;356(9223):26-30.
85. RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S. Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med.* 2009, 361(17):1627-1638. (Free)
86. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med.* 2008 Jul 3;359(1):7-20. doi: 10.1056/NEJMoa0802639. Epub 2008 May 20.(Free)

87. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, Kaplan RM; Collaborative Group for Treatment of ARF in the ICU. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. *Kidney Int.* 2001 Sep;60(3):1154-63. (Free)
88. Is peritoneal dialysis adequate for hypercatabolic acute renal failure in developing countries? Chitalia VC, Almeida AF, Rai H, Bapat M, Chitalia KV, Acharya VN, Khanna R. *Kidney Int.* 2002 Feb;61(2):747-57. (Free)
89. Phu NH, Hien TT, Mai NT, Chau TT, Chuong LV, Loc PP, Winearls C, Farrar J, White N, Day N. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. *N Engl J Med.* 2002 Sep 19;347(12):895-902. (Free)
90. Gabriel DP, Caramori JT, Martim LC, Barretti P, Balbi AL. High volume peritoneal dialysis versus daily hemodialysis: a randomized, controlled trial in patients with acute kidney injury. *Kidney Int Suppl.* 2008 Apr;(108):S87-93 (Free)
91. George J, Varma S, Kumar S, Thomas J, Gopi S, Pisharody R. Comparing continuous venovenous hemodiafiltration and peritoneal dialysis in critically ill patients with acute kidney injury: a pilot study. *Perit Dial Int.* 2011 Jul-Aug;31(4):422-9. doi: 10.3747/pdi.2009.00231. Epub 2011 Feb 28. (Free)
92. Coca SG, Yalavarth R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. *Kidney Int.* 2008 May;73(9):1008-16. Epub 2007 Dec 19. (Free)
93. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. *J Am Coll Cardiol.* 2008 Nov 4;52(19):1527-39. (Free)
94. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO; EUVAS (European Vasculitis Study Group) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med.* 2009 May 19;150(10):670-80.
95. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum.* 2005 Aug;52(8):2461-9. (Free)
96. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD, European Vasculitis Study Group : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 18: 2180–2188, 2007. (Free)
97. Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J.W., Dadonien J., Ekstrand, A., Gaskin, G. Gregorini, G. De Groot, K. A randomized trial of

maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003; 349, 36-44.

98. Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, Hauser T, Neumann I, Tesar V, Wissing KM, Pagnoux C, Schmitt W, Jayne DR; European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. *JAMA*. 2010 Dec 1;304(21):2381-8.
99. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905. (Free)
100. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med*. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169. (Free)
101. Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noël LH, Pusey CD, Waldherr R, Buijn JA, Bajema IM. Histopathologic classification of ANCA-associated glomerulonephritis. *J Am Soc Nephrol*. 2010 Oct;21(10):1628-36. doi: 10.1681/AS. (Free)
102. Sharma BK, Jain S, Suri S, Numano F. *Int J Cardiol*. 1996 Aug;54 Suppl:S141-7. Diagnostic criteria for Takayasu arteritis.
103. Stone JH, Zen Y, Deshpande V. IgG4-related disease. *N Engl J Med*. 2012;366:539-51.
104. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med*. 2002 Dec 19;347(25):2010-9. (Free)
105. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). *Kidney Int*. 1985 Sep;28(3):526-34. (Free)
106. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcome. *J Am Soc Nephrol* 1996; 7:198-207. (Free)
107. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al, for the Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal



clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol* 2002; 13:1307–20.(Free)

108. Brown EA, Davies SJ, Rutherford P, Meeus F, Borrás M, Riegel W, Divino Filho JC, Vonesh E, van Bree M; EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APDO Outcome Study. *J Am Soc Nephrol*. 2003 Nov;14(11):2948-57.(Free)
109. Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, Krediet RT. NECOSAD Study Group. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. *Kidney Int*. 2003 Dec;64(6):2222-8. (Free)
110. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, Ma JZ. Mortality risks of peritoneal dialysis and hemodialysis. *Am J Kidney Dis*. 1999 Dec;34(6):1065-74.
111. Snell GD. Methods for the study of histocompatibility genes. *Journal of Genetics* 49(2);87-108;1948 (Free)
112. J. Dausset. Iso-Leucoantigens. *Acta Haematol*. 20; 156-66: 1958 (Free)
113. Terasaki PI, McClelland JD Microdroplet Assay of Human Serum Cytotoxins *Nature* 204, 998 - 1000 (05 December 1964); doi:10.1038/204998b0 (Free)
114. U Francke and M A Pellegrino. Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. *Proc Natl Acad Sci U S A*. Mar 1977; 74(3): 1147–1151. (Free)
115. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. *N Engl J Med*. 1995 Aug 10;333(6):333-6. (Free)
116. Trivedi HL, Vanikar AV, Vakil JM, Shah VR, Modi PR, Trivedi VBA strategy to achieve donor-specific hyporesponsiveness in cadaver renal allograft recipients by donor haematopoietic stem cell transplantation into the thymus and periphery. *Nephrol Dial Transplant*. 2004 Sep;19(9):2374-7.(Free)
117. Induction Antibody Therapy in Kidney Transplantation. Aparna Padiyar, Joshua J. Augustine, Donald E. Hricik, *American Journal of Kidney Diseases*, Vol 54, No 5 (November), 2009: pp 935-944.
118. Bruno S, Remuzzi G, Ruggenenti P. Transplant renal artery stenosis. *J Am Soc Nephrol*. 2004 Jan;15(1):134-41.(Free)
119. John GT, Date A, Vincent L, et al. A timetable for infections after renal transplantation in the tropics. *Transplantation* 1996, 61:970 – 972
120. George Tharayil John, Viswanathan Shankar, Abi Mookanottle Abraham, Uma Mukundan, Paulose Punnakuzhathil Thomas and Chakko Korula Jacob. Risk factors for post-transplant tuberculosis. *Kidney International* (2001) 60, 1148–1153; doi:10.1046/j.1523-1755.2001.0600031148.x (Free)

121. Rapur Ram, Shantveer Uppin, Guditi Swarnalatha, Madhav Desai, Megha Harke, Neela Prasad and Kaligotla V Dakshinamurty Isolated skin ulcers due to Mycobacterium tuberculosis in a renal allograft recipient Nature Clinical Practice Nephrology December 2007; 3( 12);688-693 (Free)
122. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, & Valente M. (2008). Banff' 07 classification of renal allograft pathology: updates and future directions. Am J Transplant, Vol. 8, No. 4, pp. 753-60. (Free)
123. Wiseman AC. Polyomavirus Nephropathy: A Current Perspective and Clinical Considerations. Am J Kidney Dis. 2009 Jul;54(1):131-42. doi: 10.1053/j.ajkd.2009.01.271. Epub 2009 Apr 25.
124. Georgi Abraham, George T. John, Shroff Sunil, Edwin M. Fernando, Yogesh N.V. Reddy Evolution of renal transplantation in India over the last four decades. NDT Plus (2010) 3 (2): 203-207. doi: 10.1093/ndtplus/sfp178. (Free)
125. Davenport A, Gura V, Ronco C, Beizai M, Ezon C, Rambod E. A wearable haemodialysis device for patients with end-stage renal failure: a pilot study. Lancet. 2007 Dec 15;370(9604):2005-10.
126. Ronco C, Fecondini L. The Vicenza wearable artificial kidney for peritoneal dialysis (ViWAK PD). Blood Purif. 2007;25(4):383-8. Epub 2007 Sep 3. (Free)
127. Mani MK. Experience with a programme for prevention of chronic renal failure in India. Kidney Int Suppl. 2005;94:S75-8.
128. Chugh KS. Five decades of Indian nephrology: a personal journey. Am J Kidney Dis. 2009 Oct;54(4):753-63. doi: 10.1053/j.ajkd.2009.06.027. Epub 2009 Sep 2. (Free)
129. William B. Schwartz, Warren Bennett, Sidney Curelop, Frederic C. Bartter. A Syndrome of Renal Sodium Loss and Hyponatremia Probably Resulting from Inappropriate Secretion of Antidiuretic Hormone. J Am Soc Nephrol 12: 2860-2870, 2001; reprinted from Am J Med 23: 529-542; 1957 (Free)
130. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13;160(5):685-93. (Free)
131. Goodpasture, Ernest W. The significance of certain pulmonary lesions in relation to the etiology of influenza. American Journal of the Medical Sciences: November 1919 - Volume 158 - Issue 6 - ppg 863-870
132. Lerner RA, Glasscock RJ, Dixon FJ The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. The Journal of Experimental Medicine vol. 126 , 1967:989-1004

133. Stanton MC, Yange JD, Good pasture's syndrome (Pulmonary hemorrhage associated with glomerulonephritis), *Australia Med* – 1958.01.132
134. Seabra VF, Balk EM, Liangos O, Sosa MA, Cendoroglo M, Jaber BL. Timing of renal replacement therapy initiation in acute renal failure: a meta-analysis. *Am J Kidney Dis*. 2008 Aug;52(2):272-84
135. Merrill JP, Murray JE, Harrison JH, Guild WR. Successful Homotransplantation Of The Human Kidney Between Identical Twins. *J Am Med Assoc*. 1956 Jan 28;160(4):277-82.
136. Murray JE, Merrill JP, Harrison JH, Wilson RE, Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. *N Engl J Med*. 1963 Jun 13;268:1315-23
137. Starzl TE, Marchioro TL, Waddell WR The Reversal of rejection in human renal homografts with subsequent development of homograft tolerance. *Surg Gynecol Obstet*. 1963 Oct;117:385-95. (Free)
138. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. *Lancet*. 1966 Sep 24;2(7465):662-5.
139. Belzer FO, Ashby BS, Gulyassy PF, Powell M. Successful seventeen-hour preservation and transplantation of human-cadaver kidney. *N Engl J Med*. 1968 Mar 14;278(11):608-10.
140. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. *Lancet*. 1978 Dec 23-30;2(8104-5):1323-7. (Free)
141. Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, Held E, Riethmüller G, Land W, Albert E. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. *Clin Exp Immunol*. 1991 Dec;86(3):464-70. (Free)
142. Ratner LE , Ciseck LJ , Moore RG , Cigarroa FG , Kaufman HS , Kavoussi LRLaparoscopic live donor nephrectomy. *Transplantation* 1995, 60(9):1047-1049
143. Tanabe K, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, Kawai T, Fuchinoue S, Oshima T, Yagisawa T, Nakazawa H, Goya N, Koga S, Kawaguchi H, Ito K, Toma H, Agishi T, Ota K. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. *Transplantation*. 1998 Jan 27;65(2):224-8.
144. Robert P. Popovich, Jack W. Moncrief, Karl D. Nolph, Ahad J. Ghods, Zbylut J. Twardowski, W. K. Pyle. Continuous Ambulatory Peritoneal Dialysis. *Ann Intern Med*. 1978;88(4):449-456. doi:10.7326/0003-4819-88-4-449
145. Twardowski Z.J. Clinical Value of Standardized Equilibration Tests in CAPD Patients *Blood Purif* 1989;7:95–108 (DOI:10.1159/000169582)
146. Bengt Rippe, Gunnar Stelin, Börje Haraldsson. Computer simulations of peritoneal fluid transport in CAPD *Kidney Int* 40: 315-325; doi:10.1038/ki.1991.216 (Free)
147. Chandra D Mistry, Ram Gokal and Elizabeth Peers and the MIDAS Study Group. A randomized multicenter clinical trial comparing isosmolar Icodextrin with

- hyperosmolar glucose solutions in CAPD. *Kidney Int* 46: 496-503; doi:10.1038/ki.1994.300. (Free)
148. Simon J. Davies, Louise Phillips, Patrick F. Naish, Gavin I. Russell. Peritoneal Glucose Exposure and Changes in Membrane Solute Transport with Time on Peritoneal Dialysis. *JASN* May 1, 2001 12:1046-1051 (Free)
  149. Michaela C. Brown, Keith Simpson, Jan J. Kerssens, Robert A. Mactier, and on behalf of the Scottish Renal Registry. Encapsulating Peritoneal Sclerosis in the New Millennium: A National Cohort Study. *CJASN* July 2009 4:(7)1222-1229 (Free)
  150. Jean Ethier, David C. Mendelssohn, Stacey J. Elder, Takeshi Hasegawa, Tadao Akizawa, Takashi Akiba, Bernard J. Canaud, and Ronald L. Pisoni. Vascular access use and outcomes: an international perspective from the dialysis outcomes and practice patterns study. *Nephrol. Dial. Transplant.* (2008)23 (10):3219-3226 doi:10.1093/ndt/gfn261 (Free)
  151. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, Himmelfarb J, Vazquez MA, Gassman JJ, Greene T, Radeva MK, Braden GL, Ikizler TA, Rocco MV, Davidson IJ, Kaufman JS, Meyers CM, Kusek JW, Feldman HI; Dialysis Access Consortium Study Group. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. *JAMA.* 2008 May 14;299(18):2164-71. doi: 10.1001/jama.299.18.2164. (Free)
  152. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis.* 1998 Nov;32(5 Suppl 3):S112-9.
  153. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. *Circulation.* 2005 Oct 25;112(17):2627-33. (Free)
  154. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB.
  155. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med.* 2000 May 18;342(20):1478-83. (Free)
  156. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. *Hypertension.* 2001 Oct;38(4):938-42. (Free)
  157. Henrik Ekberg, Helio Tedesco-Silva, Alper Demirbas, Štefan Vítko, Björn Nashan, Alp Gürkan, Raimund Margreiter, Christian Hugo, Josep M. Grinyó, Ulrich Frei, Yves Vanrenterghem, Pierre Daloze, Philip F. Halloran for the ELITE–Symphony Study. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. *N Engl J Med* 2007; 357:2562-2575 December 20, 2007 DOI: 10.1056/NEJMoa067411 (Free)
  158. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F; ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. *Lancet.* 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19.
  159. ATC 2013: Everolimus in Kidney Transplantation – HERAKLES trial. Posted on May 24, 2013 by AJKD blog in Meeting Coverage

160. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (BK) isolated from urine after transplantation. *Lancet* 1971;1:1253–57
161. Siedlecki, W. Irish, D. C. Brennan. Delayed Graft Function in the Kidney Transplant. *American Journal of Transplantation* 2011; 11: 2279–2296 (Free)
162. Julio Pascual Everolimus in clinical practice—renal transplantation. *Nephrol Dial Transplant* (2006) 21 [Suppl 3]: iii18–iii23 doi:10.1093/ndt/gfl300 (Free)
163. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. *N Engl J Med.* 1995 Aug 10;333(6):333-6. (Free)
164. Hargovind L. Trivedi, Aruna V. Vanikar, Javed M. Vakil, Veena R. Shah, Pranjal R. Modi, Varsha B. Trivedi A strategy to achieve donor-specific hyporesponsiveness in cadaver renal allograft recipients by donor haematopoietic stem cell transplantation into the thymus and periphery. *Nephrol. Dial. Transplant.* (2004)19 (9): 2374-2377. doi: 10.1093/ndt/gfh274 (Free)
165. Sandra Sabatini, Neil A. Kurtzman Bicarbonate Therapy in Severe Metabolic Acidosis. *JASN* April 2009 vol. 20 no. 4 692-695 (Free)
166. Yile Chen, Qiang Tai, Shaodong Hong, Yuan Kong, Yushu Shang, Wenhua Liang, Zhiyong Guo, Xiaoshun He. Pretransplantation Soluble CD30 Level As a Predictor of Acute Rejection in Kidney Transplantation: A Meta-Analysis. *Transplantation* 2012;94: 911Y918
167. Alport AC. Hereditary familial congenital haemorrhagic nephritis. *British Medical Journal* 1927; I, 504-506
168. Bartter FC, Pronove P, Gill Jr JR, MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. *American Journal of Medicine* 1962; 33:811-828
169. Potter EL. Normal and abnormal development of the kidney. Published by Year Book Medical Publishers, Chicago, USA, 1972
170. Reeders ST, Breuning MH, Davies KE, Nicholls RD, Jaraman Ap, Higgs Dr, Pearson PL, Weatherall DJ. A highly polymorphic DNA marker linked to adult polycystic kidney disease on chromosome 16. *Nature* 1985; 317:542-544
171. Rosenthal W, Seibold A, Antaamian A, Lonegran M, Arthus MF, Hendy GN, Birnbaumer M, Bichet DG. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. *Nature* 1992; 359:233-235
172. Latif F, Tory K, Gnarr J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science.* 1993 May 28;260(5112):1317-20.
173. Wrong OM, Norden AGW, Feest TG. Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. *QJM*(1994)87 (8): 473-493 DOI: <http://dx.doi.org/First> published online: 1 August 1994 (21 pages)
174. Sanyanusin P, Schimmenti LA, McNoe LA, Ward TA, Pierpont ME, Sullivan MJ, Dobyns WB, Eccles MR Mutations of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteric reflux. *Nat Genet.* 1995 Apr;9(4):358-64.
175. Michael J. Brescia, M.D., James E. Cimino, M.D., Kenneth Appel, M.D., and Baruch J. Hurwich, M.D. Chronic Hemodialysis Using Venipuncture and a Surgically

- Created Arteriovenous Fistula. *N Engl J Med* 1966; 275:1089-1092, November 17, 1966. DOI: 10.1056/NEJM196611172752002
177. Page I. The production of persistent arterial hypertension by cellophane nephritis. *JAMA* 1939;113/2046 – 2048
178. Engel WJ, Page IH. Hypertension due to renal compression resulting from subcapsular hematoma *J Urol.*1955;73(5):735-9
179. M. Takayasu. A case with peculiar changes of the central retinal vessels. *Acta Societatis ophthalmologicae Japonicae*, Tokyo 1908, 12: 554
180. Scott C. Howard, Deborah P. Jones, Ching-Hon Pui, The Tumor Lysis Syndrome. *N Engl J Med* 2011;364:1844-54
181. Winn MP, Conlon PJ, Lynn KL, Howell DN, Gross DA, Rogala AR, Smith AH, Graham FL, Bembe M, Quarles LD, Pericak-Vance MA, Vance JM. Clinical and genetic heterogeneity in familial focal segmental glomerulosclerosis. International Collaborative Group for the Study of Familial Focal Segmental Glomerulosclerosis. *Kidney Int.* 1999 Apr;55(4):1241-6. (Free)
182. Arniel GC, Wilson HE. Cortisone treatment in Nephrosis. *Archives of Disease in Childhood* 1952; 27:322-328 (Free)
183. Muehrcke RC, Kark RM, Pirani CL, Pollak VE. Lupus nephritis: a clinical and pathologic study based on renal biopsies. *Medicine (Baltimore)*, 1957; 36:1-145
184. Pollak VE, Pirani CL, Kark RM. Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. *Journal of Laboratory and Clinical Medicine* 1961; 57:495-511
185. Brin C, Gormsen H, Hilden T, Iversen P, Rasschou F. Diabetic nephropathy: kidney biopsy and renal function tests. *American Journal of Medicine* 1953; 15: 187-197
186. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA.* 2002 Nov 20;288(19):2421-31. (Free)
187. Christopher W. McIntyre, James O. Burton, Nicholas M. Selby, Lucia Leccisotti, Shvan Korsheed, Christopher S.R. Baker, and Paolo G. Camici. Hemodialysis-Induced Cardiac Dysfunction Is Associated with an Acute Reduction in Global and Segmental Myocardial Blood Flow. *Clin J Am Soc Nephrol* 3: 19 –26, 2008. doi: 10.2215/CJN.03170707 (Free)
188. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF Jr, Glockner JF, Wetzel LH, Brummer ME, O'Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. *Kidney Int.* 2003 Sep;64(3):1035-45. (Free)
189. Jacobson LO, Goldwasser E, Fried W, Plizak L Role of the kidney in erythropoiesis. *Nature.* 1957 Mar 23;179(4560):633-4.

190. Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, M.D., Eiji Higashihara, M.D., Ph.D., Ronald D. Perrone, M.D., Holly B. Krasa, M.S., John Ouyang, Frank S. Czerwiec, for the TEMPO 3:4 Trial Investigators\**Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease*. *N Engl J Med* 2012;367:2407-18.
191. Shizuko Nagao, Kazuhiro Nishii, Makoto Katsuyama, Hiroki Kurahashi, Tohru Marunouchi, Hisahide Takahashi, Darren P. Wallace. Increased Water Intake Decreases Progression of Polycystic Kidney Disease in the PCK Rat. *J Am Soc Nephrol* 17: 2220–2227, 2006. doi: 10.1681/ASN.2006030251 (Free)
192. Suresh Kumar KK, Hussain SM. Carpenter BJ, Sandroni SE, Marcus RJ. Antibody-mediated rejection following renal transplantation. *Expert Opin Pharmacother*. 2007; 8(7): 913-921
193. Frank P. Hurst, Kevin C. Abbott, Robert T. Neff, Eric A. Elster, Edward M. Falta, Krista L. Lentine, Lawrence Y. Agodoa, Rahul M. Jindal. Incidence, Predictors and Outcomes of Transplant Renal Artery Stenosis after Kidney Transplantation: Analysis of USRDS. *Am J Nephrol* 2009;30:459–467 DOI: 10.1159/000242431 (Free).
194. Luis Callís, Angel Vila, Marta Carrera, José Nieto. Long-term effects of cyclosporine A in Alport's syndrome. *Kidney Int* 55: 1051-1056; doi:10.1046/j.1523-1755.1999.0550031051. (Free)
195. Yachnin T, Iaina A, Schwartz D, Nakache R The mother of an Alport's syndrome patient: a safe kidney donor? *Nephrol Dial Transplant*. 2002 Apr;17(4):683-4. (Free)
196. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost*. 2006 Feb;4(2):295-306. (Free)
197. Jerrold S. Levine, D. Warebranch, Joyce Rauch. The Antiphospholipid Syndrome. *N Engl J Med*, Vol. 346, No. 10· March 7, 2002, 752-763 (Free)
198. Rashad S. Barsoum Malarial Acute Renal Failure. *J Am Soc Nephrol* 11: 2147–2154, 2000 (Free)
199. Muthusethupathi MA, Shivakumar S, Suguna R, Jayakumar M, Vijayakumar R, Everard CO, Carrington D G Leptospirosis in Madras--a clinical and serological study. *J Assoc Physicians India*. 1995 Jul;43(7):456-8 (Free)
200. Xavier Bosch, Esteban Poch, Josep M. Grau, Rhabdomyolysis and Acute Kidney Injury. *N Engl J Med* 2009; 361:62-72 July 2, 2009 DOI: 10.1056/NEJMra0801327
201. Richard A. Zager. Rhabdomyolysis and myohemoglobinuric acute renal failure. *Kidney International*, Vol. 49 (1996), pp. 314—326 (Free)
202. Mitchell H. Rosner, Justin Kirve. Exercise-Associated Hyponatremia. *Clin J Am Soc Nephrol* 2: 151–161, 2007. doi: 10.2215/CJN.02730806. (Free)
203. Seung Hyeok Han, Sang Choel Lee, Song Vogue Ahn, Jung Eun Lee, Hoon Young Choi, Beom Seok Kim, Shin-Wook Kang, Kyu Hun Choi, Dae Suk Han, Ho Yung Lee Improving Outcome Of Capd: Twenty-Five Years' Experience In A Single Korean Center. *Peritoneal Dialysis International*, Vol. 27, pp. 432–440. (Free)
204. Poul Iversen, Claus Brun, Aspiration biopsy of the kidney *American Journal of Medicine* September 1951 Volume 11, Issue 3, Pages 324–330
205. K S Chugh *Nephrology Forum: Snake-bite-induced acute renal failure in India* *Kidney International* (1989) 35, 891–907; doi:10.1038/ki.1989.70 (Free)

206. Kohli HS, Sakhuja V. Snake Bites and Acute Renal Failure. *Saudi J Kid Dis Trans.* 2003; 14: 2: 165-176 (Free)
207. Visith Sitprijia *Nephrology Forum: Nephropathy in falciparum malaria.* *Kidney International*, Vol. 34 (1988), pp. 867—877 (Free)
208. Joshua J. Augustine, Donald E. Hricik. Steroid Sparing in Kidney Transplantation: Changing Paradigms, Improving Outcomes, and Remaining Questions. *Clin J Am Soc Nephrol*: 1080–1089, 2006. doi: 10.2215/CJN.01800506 (Free)
209. Maurizio Salvadori, Elisabetta Berton Is it time to give up with calcineurin inhibitors in kidney transplantation? *World J Transplant* 2013 June 24; 3(2): 7-25 (Free)
210. V Gura, C Ronco, F Nalesso, A Brendolan, M Beizai, C Ezon, A Davenport, E Rambod. A wearable hemofilter for continuous ambulatory ultrafiltration. *Kidney International*(2008) 73, 497–502; doi:10.1038/sj.ki.5002711 (Free)
211. Andrew Davenport, Victor Gura, Claudio Ronco, Masoud Beizai, Carlos Ezon, Edmond Rambod A wearable haemodialysis device for patients with end-stage renal failure: a pilot study 2007; 370 No. 9604; 2005-2010
212. Dimitrios G. Oreopoulos The *Nephrology Forum: The optimization of continuous ambulatory peritoneal dialysis.* *Kidney International*, Vol. 55 (1999), pp. 1131–1149 (Free)
213. SG Coca, R Yalavarthy, J Concato, CR Parikh. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. *Kidney Int.* 2008 May;73(9):1008-16. Epub Dec 19. (Free)
214. A Meyrier. Cholesterol crystal embolism: Diagnosis and treatment *Kidney International*(2006) 69,1308–1312. doi:10.1038/sj.ki.5000263 (Free)
215. Vijay Kher *Nephrology Forum. End-stage renal disease in developing countries.* *Kidney International*, Vol. 62 (2002), pp. 350–362 (Free)
216. Mignon F, Méry JP, Mougnot B, Ronco P, Roland J, Morel-Maroger L. Granulomatous interstitial nephritis. *Adv Nephrol Necker Hosp.* 1984;13:219-45.
217. M. Krishna Mani, *Treating Renal Disease in India's Poor: The Art of the Possible* *Semin Nephrol* 30:74-80 2010
218. Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi MA. Acute renal failure due to rifampicin: a study of 25 patients. *Am J Kidney Dis.* 2002 Oct;40(4):690-6.
219. Robert A. Wolfe, Valarie B. Ashby, Edgar L. Milford, Akinlolu O. Ojo, Robert E. Ettenger, Lawrence Y.C. Agodoa, Philip J. Held, Friedrich K. Port, Comparison Of Mortality In All Patients On Dialysis, Patients On Dialysis Awaiting Transplantation, And Recipients Of A First Cadaveric Transplant. *N Engl J Med* 1999;341:1725-30. (Free)
220. Walton RJ, Bijvoet OLM. Nomogram for Derivation of Renal Threshold Phosphate Concentration. *The Lancet* August 16, 1975:309-310
221. Kenneth F. Fairley Douglas F. Birch Hematuria: A simple method for identifying glomerular bleeding *Kidney International*, Vol. 21(1982), pp. 105—108 (Free)
222. Hans Kohler, Eveline Wandel, Bernd Brunck. Acanthocyturia—A characteristic marker for glomerular bleeding. *Kidney International*, Vol. 40 (1991), pp. 115—120 (Free)
223. B. E. Tomlinson, A. M. Pierides And W. G. Bradley Central Pontine Myelinolysis. Two Cases With Associated Electrolyte Disturbance. *Quarterly Journal of Medicine, New Series, XLV, No. 179 pp 373-86, July 1976*



224. Robert S. Dobrin, Robert L. Vernier, Alfred J. Fish. Acute Eosinophilic Interstitial Nephritis and Renal Failure with Bone Marrow-Lymph Node Granulomas and Anterior Uveitis A New Syndrome The American Journal of Medicine September 1975 Volume 59 325-333
225. Ramsey PG, Rubin RH, Tolkoff-Rubin NE, Cosimi AB, Russell PS, Greene R. The renal transplant patient with fever and pulmonary infiltrates: Etiology, clinical manifestations, and management., *Medicine (Baltimore)*. 1980 May;59(3):206-22
226. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. *Am J Med* 1981;70: 405-411.